MICHAEL J FOX FOUNDATION FOR PARKINSONS RESEARCH: Form 990, tax year 2010

View the entire original 990 at ProPublica ↗

Organization: MICHAEL J FOX FOUNDATION FOR PARKINSONS RESEARCH (EIN 13-4141945)
Tax period: 2010-01-01 to 2010-12-31
Filed: 2011-06-22
IRS object ID: 201101739349300705
Schema version: 2010v3.2
Note: A later return for the same period supersedes this one.
Source: Download XML · Original 990 at ProPublica

Every field in the e-filed return. Faint text is the IRS element name, for citing.

Return header
Form 990
Schedule A
Schedule B
Schedule D
Schedule F
Schedule G
Schedule I
Schedule J
Schedule L
Schedule M
Schedule O
Schedule R

Return header ReturnHeader

Field	Value	IRS element (for citing)
Timestamp	2011-06-22T14:51:24-04:00	Timestamp
Tax Period End Date	2010-12-31	TaxPeriodEndDate

Preparer Firm PreparerFirm

Preparer Firm Business Name PreparerFirmBusinessName

Field	Value	IRS element (for citing)
Business Name Line1	EISNERAMPER LLP	BusinessNameLine1

Preparer Firm US Address PreparerFirmUSAddress

Field	Value	IRS element (for citing)
Address Line1	750 THIRD AVENUE	AddressLine1
City	NEW YORK	City
State	NY	State
ZIP Code	100172703	ZIPCode

Field	Value	IRS element (for citing)
Return Type	990	ReturnType
Tax Period Begin Date	2010-01-01	TaxPeriodBeginDate

Filer Filer

Field	Value	IRS element (for citing)
EIN	134141945	EIN

Name Name

Field	Value	IRS element (for citing)
Business Name Line1	THE MICHAEL J FOX FOUNDATION	BusinessNameLine1
Business Name Line2	FOR PARKINSON'S RESEARCH	BusinessNameLine2

Field	Value	IRS element (for citing)
Name Control	MICH	NameControl
Phone	2125090995	Phone

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	CHURCH STREET STATION PO BOX 780	AddressLine1
City	NEW YORK	City
State	NY	State
ZIP Code	100080780	ZIPCode

Officer Officer

Field	Value	IRS element (for citing)
Name	Joanne Martz	Name
Title	Chief Fin/Admin Officer	Title
Date Signed	2011-06-15	DateSigned

Preparer Preparer

Field	Value	IRS element (for citing)
Phone	2129498700	Phone

Field	Value	IRS element (for citing)
Tax Year	2010	TaxYear
Build TS	2016-02-24 21:20:13Z	BuildTS

Form 990 IRS990

Field	Value	IRS element (for citing)
Name Of Principal Officer Person	Todd Sherer	NameOfPrincipalOfficerPerson

Address Principal Officer US AddressPrincipalOfficerUS

Field	Value	IRS element (for citing)
Address Line1	Church Street Station PO 780	AddressLine1
City	New York	City
State	NY	State
ZIP Code	10008	ZIPCode

Field	Value	IRS element (for citing)
Gross Receipts	106255595	GrossReceipts
Group Return For Affiliates	false	GroupReturnForAffiliates
Organization501c3	X	Organization501c3
Web Site	www.michaeljfox.org	WebSite
Type Of Organization Corporation	X	TypeOfOrganizationCorporation
Year Formation	2000	YearFormation
State Legal Domicile	DE	StateLegalDomicile
Activity Or Mission Description	THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH IS DEDICATED TO ENSURING THE DEVELOPMENT OF BETTER TREATMENTS, AND ULTIMATELY A CURE, FOR PARKINSON'S DISEASE THROUGH AN AGRESSIVELY FUNDED RESEARCH AGENDA.	ActivityOrMissionDescription
Nbr Voting Members Governing Body	26	NbrVotingMembersGoverningBody
Nbr Independent Voting Members	24	NbrIndependentVotingMembers
Total Nbr Employees	68	TotalNbrEmployees
Total Nbr Volunteers	7	TotalNbrVolunteers
Total Gross UBI	28493	TotalGrossUBI
Net Unrelated Business Txbl Income	10807	NetUnrelatedBusinessTxblIncome
Contributions Grants Prior Year	51252077	ContributionsGrantsPriorYear
Contributions Grants Current Year	57111106	ContributionsGrantsCurrentYear
Program Service Revenue Prior Year	0	ProgramServiceRevenuePriorYear
Program Service Revenue CY	0	ProgramServiceRevenueCY
Investment Income Prior Year	99438	InvestmentIncomePriorYear
Investment Income Current Year	476177	InvestmentIncomeCurrentYear
Other Revenue Prior Year	37425	OtherRevenuePriorYear
Other Revenue Current Year	34177	OtherRevenueCurrentYear
Total Revenue Prior Year	51388940	TotalRevenuePriorYear
Total Revenue Current Year	57621460	TotalRevenueCurrentYear
Grants And Similar Amnts Prior Year	34683415	GrantsAndSimilarAmntsPriorYear
Grants And Similar Amnts CY	49441851	GrantsAndSimilarAmntsCY
Benefits Paid To Members Prior Year	0	BenefitsPaidToMembersPriorYear
Benefits Paid To Members CY	0	BenefitsPaidToMembersCY
Salaries Etc Prior Year	5431685	SalariesEtcPriorYear
Salaries Etc Current Year	6107055	SalariesEtcCurrentYear
Total Prof Fundrsng Exp Prior Year	57500	TotalProfFundrsngExpPriorYear
Total Prof Fundrsng Exp CY	49600	TotalProfFundrsngExpCY
Total Fundrsng Exp Current Year	4137564	TotalFundrsngExpCurrentYear
Other Expense Prior Year	4179531	OtherExpensePriorYear
Other Expenses Current Year	4458038	OtherExpensesCurrentYear
Total Expenses Prior Year	44352131	TotalExpensesPriorYear
Total Expenses Current Year	60056544	TotalExpensesCurrentYear
Revenues Less Expenses Prior Year	7036809	RevenuesLessExpensesPriorYear
Revenues Less Expenses CY	-2435084	RevenuesLessExpensesCY
Total Assets BOY	69013965	TotalAssetsBOY
Total Assets EOY	78224899	TotalAssetsEOY
Total Liabilities BOY	44985964	TotalLiabilitiesBOY
Total Liabilities EOY	56622447	TotalLiabilitiesEOY
Net Assets Or Fund Balances BOY	24028001	NetAssetsOrFundBalancesBOY
Net Assets Or Fund Balances EOY	21602452	NetAssetsOrFundBalancesEOY
Mission Description	THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH IS DEDICATED TO ENSURING THE DEVELOPMENT OF BETTER TREATMENTS, AND ULTIMATELY A CURE, FOR PARKINSON'S DISEASE THROUGH AN AGRESSIVELY FUNDED RESEARCH AGENDA.	MissionDescription
Significant New Program Services	false	SignificantNewProgramServices
Significant Change	false	SignificantChange
Expense	54545702	Expense
Grants	49441852	Grants
Description	TO FUND RESEARCH FOCUSED ON DEVELOPING A CURE FOR PARKINSON'S DISEASE.	Description
Total Program Service Expense	54545702	TotalProgramServiceExpense
Described In501 C3	true	DescribedIn501C3
Schedule B Required	true	ScheduleBRequired
Political Activities	false	PoliticalActivities
Lobbying Activities	false	LobbyingActivities
Donor Advised Funds	false	DonorAdvisedFunds
Conservation Easements	false	ConservationEasements
Collections Of Art	false	CollectionsOfArt
Credit Counseling	false	CreditCounseling
Term Or Permanent Endowments	false	TermOrPermanentEndowments
Report Land Bldg Equip	true	ReportLandBldgEquip
Report Invest Oth Securities	false	ReportInvestOthSecurities
Report Prog Rel Invest	false	ReportProgRelInvest
Report Other Assets	false	ReportOtherAssets
Report Other Liabilities	true	ReportOtherLiabilities
Report Fin48 Footnote	true	ReportFin48Footnote
Independent Audit Financial Stmt	false	IndependentAuditFinancialStmt
Consolidated Audit Financial Stmt	true	ConsolidatedAuditFinancialStmt
School	false	School
Foreign Office	true	ForeignOffice
Foreign Activities	true	ForeignActivities
More Than5000 K To Organizations	true	MoreThan5000KToOrganizations
More Than5000 K To Individuals	true	MoreThan5000KToIndividuals
Professional Fundraising	true	ProfessionalFundraising
Fundraising Activities	true	FundraisingActivities
Gaming	false	Gaming
Hospital	false	Hospital
Grants To Organizations	true	GrantsToOrganizations
Grants To Individuals	true	GrantsToIndividuals
Schedule J Required	true	ScheduleJRequired
Tax Exempt Bonds	false	TaxExemptBonds
Excess Benefit Transaction	false	ExcessBenefitTransaction
Prior Excess Benefit Transaction	false	PriorExcessBenefitTransaction
Loan To Officer Or DQP	false	LoanToOfficerOrDQP
Grant To Related Person	false	GrantToRelatedPerson
Bsnss Rltnshp With Organization	false	BsnssRltnshpWithOrganization
Bsnss Rltnshp Thru Family Member	false	BsnssRltnshpThruFamilyMember
Officer Entity With Bsnss Rltnshp	true	OfficerEntityWithBsnssRltnshp
Deductible Non Cash Contributions	true	DeductibleNonCashContributions
Deductible Contributions Of Art	false	DeductibleContributionsOfArt
Terminated	false	Terminated
Partial Liquidation	false	PartialLiquidation
Disregarded Entity	false	DisregardedEntity
Related Entity	true	RelatedEntity
Related Org Controlled Entity	false	RelatedOrgControlledEntity
Transaction Related Entity	false	TransactionRelatedEntity
Transfers To Exempt Non Chrtbl Org	false	TransfersToExemptNonChrtblOrg
Activities Conducted Partnership	false	ActivitiesConductedPartnership
Schedule O Required	true	ScheduleORequired
Number Forms Transmitted With1096	109	NumberFormsTransmittedWith1096
Number W2 G Included	0	NumberW2GIncluded
Compliance With Backup Witholding	true	ComplianceWithBackupWitholding
Number Of Employees	68	NumberOfEmployees
Employment Tax Returns Filed	true	EmploymentTaxReturnsFiled
Unrelated Business Income	true	UnrelatedBusinessIncome
Form990-T Filed	true	Form990-TFiled
Foreign Financial Account	true	ForeignFinancialAccount
Name Of Foreign Country	CA	NameOfForeignCountry
Prohibited Tax Shelter Trans	false	ProhibitedTaxShelterTrans
Taxable Party Notification	false	TaxablePartyNotification
Non Deductible Contributions	false	NonDeductibleContributions
Quid Pro Quo Contributions	true	QuidProQuoContributions
Quid Pro Quo Disclosure	true	QuidProQuoDisclosure
Form8282 Property Disposed Of	false	Form8282PropertyDisposedOf
Funds To Pay Premiums	false	FundsToPayPremiums
Premiums Paid	false	PremiumsPaid
Indoor Tanning Services	false	IndoorTanningServices
Info In Schedule O Part VI	X	InfoInScheduleOPartVI
Nbr Voting Governing Body Members	26	NbrVotingGoverningBodyMembers
Number Independent Voting Members	24	NumberIndependentVotingMembers
Family Or Business Relationship	true	FamilyOrBusinessRelationship
Delegation Of Management Duties	false	DelegationOfManagementDuties
Changes To Organizing Docs	false	ChangesToOrganizingDocs
Material Diversion Or Misuse	false	MaterialDiversionOrMisuse
Members Or Stockholders	false	MembersOrStockholders
Election Of Board Members	false	ElectionOfBoardMembers
Decisions Subject To Approval	false	DecisionsSubjectToApproval
Minutes Of Governing Body	true	MinutesOfGoverningBody
Minutes Of Committees	true	MinutesOfCommittees
Officer Mailing Address	false	OfficerMailingAddress
Local Chapters	false	LocalChapters
Form990 Provided To Governing Body	true	Form990ProvidedToGoverningBody
Conflict Of Interest Policy	true	ConflictOfInterestPolicy
Annual Disclosure Covered Persons	true	AnnualDisclosureCoveredPersons
Regular Monitoring Enforcement	true	RegularMonitoringEnforcement
Whistleblower Policy	true	WhistleblowerPolicy
Document Retention Policy	true	DocumentRetentionPolicy
Compensation Process CEO	true	CompensationProcessCEO
Compensation Process Other	true	CompensationProcessOther
Investment In Joint Venture	false	InvestmentInJointVenture
States Where Copy Of Return Is Filed	AL	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	AK	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	AZ	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	AR	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	CA	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	CO	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	CT	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	FL	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	GA	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	IL	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	KS	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	KY	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	ME	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	MD	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	MA	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	MI	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	MN	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	MS	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	NH	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	NJ	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	NM	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	NY	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	NC	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	ND	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	OH	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	OK	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	OR	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	PA	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	RI	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	SC	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	TN	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	UT	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	VA	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	WA	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	WV	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	WI	StatesWhereCopyOfReturnIsFiled
Own Website	X	OwnWebsite
Upon Request	X	UponRequest

The Books Are In Care Of TheBooksAreInCareOf

Field	Value	IRS element (for citing)
Name Person	JOANNE MARTZ	NamePerson
Telephone Number	2125090995	TelephoneNumber

Address US AddressUS

Field	Value	IRS element (for citing)
Address Line1	CHURCH STREET STATION PO BOX 780	AddressLine1
City	NEW YORK	City
State	NY	State
ZIP Code	100080780	ZIPCode

Form990 Part VII Section A Form990PartVIISectionA (36 entries)

TitleTitle	Average Hours Per WeekAverageHoursPerWeek	Individual Trustee Or DirectorIndividualTrusteeOrDirector	Reportable Comp From OrganizationReportableCompFromOrganization	Reportable Comp From Related OrgsReportableCompFromRelatedOrgs	Other CompensationOtherCompensation	OfficerOfficer	Key EmployeeKeyEmployee	Highest Compensated EmployeeHighestCompensatedEmployee
MICHAEL J FOX
FOUNDER	2.0	X	0	0	0
HOLLY S ANDERSEN MD
MEMBER	2.0	X	0	0	0
EVA ANDERSSON-DUBIN MD
MEMBER	2.0	X	0	0	0
JON BROOKS
MEMBER	2.0	X	0	0	0
BARRY COHEN
MEMBER	2.0	X	0	0	0
DONNY DEUTSCH
MEMBER	2.0	X	0	0	0
DAVID EINHORN
MEMBER	2.0	X	0	0	0
KAREN FINERMAN
MEMBER	2.0	X	0	0	0
NELLE FORTENBERRY
MEMBER	2.0	X	0	0	0
ALBERT B GLICKMAN
MEMBER	2.0	X	0	0	0
DAVID GOLUB
VICE CHAIRMAN	2.0	X	0	0	0	X
MARK L HART III
MEMBER	2.0	X	0	0	0
KATHLEEN KENNEDY
MEMBER	2.0	X	0	0	0
MORTON M KONDRACKE
MEMBER	2.0	X	0	0	0
EDWIN A LEVY
MEMBER	2.0	X	0	0	0
SKIP IRVING
MEMBER	2.0	X	0	0	0
MARC S LIPSCHULTZ
MEMBER	2.0	X	0	0	0
TRACY POLLAN
MEMBER	2.0	X	0	0	0
DOUGLAS I OSTROVER
CHAIRMAN	2.0	X	0	0	0	X
GEORGE E PRESCOTT
MEMBER	2.0	X	0	0	0
LILY SAFRA
MEMBER	2.0	X	0	0	0
CURTIS SCHENKER
MEMBER	2.0	X	0	0	0
FREDRICK E ROWE JR
MEMBER	2.0	X	0	0	0
RYAN REYNOLDS
MEMBER	2.0	X	0	0	0
FRED G WEISS
MEMBER	2.0	X	0	0	0
ROBERT W SHACKLETON
MEMBER	2.0	X	0	0	0
KATHERINE H HOOD
CEO	40.0		470623	0	7753	X
JOANNE MARTZ
VP ADMINISTRATION	40.0		225396	0	19335	X
Todd Sherer
vp Research	40.0		325496	0	19923	X
KAREN LEIES
vp Development	40.0		222125	0	24491		X
DEBORAH W BROOKS
CO-FOUNDER	40.0		440606	0	25177		X
John T Grant
Controller	40.0		145796	0	10189			X
SHEILA KELLY
DIR. SPECIAL EVENTS & TEAM FOX	40.0		146287	0	10164			X
Brian K Fiske
Associate Director	40.0		142653	0	16626			X
Sohini Chowdhury
Associate Director	40.0		136265	0	9863			X
JAMIE L EBERLING
ASSOCIATE DIRECTOR	40.0		119754	0	9368			X

Field	Value	IRS element (for citing)
Total Reportable Comp From Org	2375001	TotalReportableCompFromOrg
Total Reportable Comp Frm Rltd Orgs	0	TotalReportableCompFrmRltdOrgs
Total Other Compensation	152889	TotalOtherCompensation
Number Individuals GT100 K	13	NumberIndividualsGT100K
Formers Listed	false	FormersListed
Total Comp GT150 K	true	TotalCompGT150K
Compensation From Other Sources	false	CompensationFromOtherSources

Contractor Compensation ContractorCompensation

Name Of Contractor NameOfContractor

Field	Value	IRS element (for citing)
Name Person	SCHANER AND LUBITZ LLC	NamePerson

Address Of Contractor AddressOfContractor

Address US AddressUS

Field	Value	IRS element (for citing)
Address Line1	6391 ARLINGTIN ROAD SUITE 200	AddressLine1
City	BETHESDA	City
State	MD	State
ZIP Code	20814	ZIPCode

Field	Value	IRS element (for citing)
Description Of Services	Legal Advice	DescriptionOfServices
Compensation	169100	Compensation

Field	Value	IRS element (for citing)
Number Of Contractors GT100 K	1	NumberOfContractorsGT100K
Fundraising Events	6988278	FundraisingEvents
Related Organizations	180240	RelatedOrganizations
All Other Contributions	49942588	AllOtherContributions
Noncash Contributions	5398435	NoncashContributions
Total Contributions	57111106	TotalContributions
Total Program Service Revenue	0	TotalProgramServiceRevenue

Investment Income InvestmentIncome

Field	Value	IRS element (for citing)
Total Revenue Column	232554	TotalRevenueColumn
Exclusion	$232,554	ExclusionAmount

Income From Invest Bond Proceeds IncomeFromInvestBondProceeds

Field	Value	IRS element (for citing)
Total Revenue Column	0	TotalRevenueColumn

Royalties Revenue RoyaltiesRevenue

Field	Value	IRS element (for citing)
Total Revenue Column	0	TotalRevenueColumn

Gross Amount Sales Assets GrossAmountSalesAssets

Field	Value	IRS element (for citing)
Securities	48484078	Securities

Less Cost Oth Basis Sales Expenses LessCostOthBasisSalesExpenses

Field	Value	IRS element (for citing)
Securities	48240455	Securities

Gain Or Loss GainOrLoss

Field	Value	IRS element (for citing)
Securities	243623	Securities

Net Gain Or Loss Investments NetGainOrLossInvestments

Field	Value	IRS element (for citing)
Total Revenue Column	243623	TotalRevenueColumn
Exclusion	$243,623	ExclusionAmount

Field	Value	IRS element (for citing)
Gross Income Fundraising Events	358540	GrossIncomeFundraisingEvents
Cntrbtns Rprtd Fundraising Events	6988278	CntrbtnsRprtdFundraisingEvents
Fundraising Direct Expenses	358540	FundraisingDirectExpenses

Net Income From Fundraising Events NetIncomeFromFundraisingEvents

Field	Value	IRS element (for citing)
Total Revenue Column	0	TotalRevenueColumn

Net Income From Gaming NetIncomeFromGaming

Field	Value	IRS element (for citing)
Total Revenue Column	0	TotalRevenueColumn

Field	Value	IRS element (for citing)
Gross Sales Of Inventory	63633	GrossSalesOfInventory
Cost Of Goods Sold	35140	CostOfGoodsSold

Net Income Or Loss NetIncomeOrLoss

Field	Value	IRS element (for citing)
Total Revenue Column	28493	TotalRevenueColumn
Unrelated Business Revenue	28493	UnrelatedBusinessRevenue

Other Revenue Misc OtherRevenueMisc

Field	Value	IRS element (for citing)
Description	MISCELLANEOUS REVENUE	Description
Total Revenue Column	5684	TotalRevenueColumn
Exclusion	$5,684	ExclusionAmount

Field	Value	IRS element (for citing)
Total Other Revenue	5684	TotalOtherRevenue

Total Revenue TotalRevenue

Field	Value	IRS element (for citing)
Total Revenue Column	57621460	TotalRevenueColumn
Unrelated Business Revenue	28493	UnrelatedBusinessRevenue
Exclusion	$481,861	ExclusionAmount

Grants To Domestic Orgs GrantsToDomesticOrgs

Field	Value	IRS element (for citing)
Total	32651054	Total
Program Services	32651054	ProgramServices

Grants To Domestic Individuals GrantsToDomesticIndividuals

Field	Value	IRS element (for citing)
Total	0	Total

Foreign Grants ForeignGrants

Field	Value	IRS element (for citing)
Total	16790797	Total
Program Services	16790797	ProgramServices

Benefits To Members BenefitsToMembers

Field	Value	IRS element (for citing)
Total	0	Total

Comp Current Officers Directors CompCurrentOfficersDirectors

Field	Value	IRS element (for citing)
Total	1773646	Total
Program Services	398838	ProgramServices
Management And General	386060	ManagementAndGeneral
Fundraising	988748	Fundraising

Comp Disqual Persons CompDisqualPersons

Field	Value	IRS element (for citing)
Total	0	Total

Other Salaries And Wages OtherSalariesAndWages

Field	Value	IRS element (for citing)
Total	3536349	Total
Program Services	2309989	ProgramServices
Management And General	504014	ManagementAndGeneral
Fundraising	722346	Fundraising

Pension Plan Contributions PensionPlanContributions

Field	Value	IRS element (for citing)
Total	103054	Total
Program Services	60866	ProgramServices
Management And General	14136	ManagementAndGeneral
Fundraising	28052	Fundraising

Other Employee Benefits OtherEmployeeBenefits

Field	Value	IRS element (for citing)
Total	342782	Total
Program Services	175679	ProgramServices
Management And General	71459	ManagementAndGeneral
Fundraising	95644	Fundraising

Payroll Taxes PayrollTaxes

Field	Value	IRS element (for citing)
Total	351224	Total
Program Services	177956	ProgramServices
Management And General	58497	ManagementAndGeneral
Fundraising	114771	Fundraising

Fees For Services Management FeesForServicesManagement

Field	Value	IRS element (for citing)
Total	0	Total

Fees For Services Legal FeesForServicesLegal

Field	Value	IRS element (for citing)
Total	127049	Total
Program Services	118500	ProgramServices
Management And General	1500	ManagementAndGeneral
Fundraising	7049	Fundraising

Fees For Services Accounting FeesForServicesAccounting

Field	Value	IRS element (for citing)
Total	48078	Total
Management And General	48078	ManagementAndGeneral

Fees For Services Lobbying FeesForServicesLobbying

Field	Value	IRS element (for citing)
Total	0	Total

Fees For Services Prof Fundraising FeesForServicesProfFundraising

Field	Value	IRS element (for citing)
Total	49600	Total
Fundraising	49600	Fundraising

Fees For Services Invst Mgmnt Fees FeesForServicesInvstMgmntFees

Field	Value	IRS element (for citing)
Total	0	Total

Fees For Services Other FeesForServicesOther

Field	Value	IRS element (for citing)
Total	257571	Total
Program Services	48905	ProgramServices
Management And General	81226	ManagementAndGeneral
Fundraising	127440	Fundraising

Advertising Advertising

Field	Value	IRS element (for citing)
Total	144442	Total
Program Services	37849	ProgramServices
Fundraising	106593	Fundraising

Office Expenses OfficeExpenses

Field	Value	IRS element (for citing)
Total	506088	Total
Program Services	200590	ProgramServices
Management And General	20646	ManagementAndGeneral
Fundraising	284852	Fundraising

Information Technology InformationTechnology

Field	Value	IRS element (for citing)
Total	194155	Total
Program Services	96116	ProgramServices
Management And General	25303	ManagementAndGeneral
Fundraising	72736	Fundraising

Royalties Royalties

Field	Value	IRS element (for citing)
Total	0	Total

Occupancy Occupancy

Field	Value	IRS element (for citing)
Total	487401	Total
Program Services	264351	ProgramServices
Management And General	67707	ManagementAndGeneral
Fundraising	155343	Fundraising

Travel Travel

Field	Value	IRS element (for citing)
Total	158746	Total
Program Services	33997	ProgramServices
Management And General	4585	ManagementAndGeneral
Fundraising	120164	Fundraising

Travel Entrtnmnt Public Officials TravelEntrtnmntPublicOfficials

Field	Value	IRS element (for citing)
Total	0	Total

Conferences Meetings ConferencesMeetings

Field	Value	IRS element (for citing)
Total	1166889	Total
Program Services	1041364	ProgramServices
Management And General	4671	ManagementAndGeneral
Fundraising	120854	Fundraising

Interest Interest

Field	Value	IRS element (for citing)
Total	48548	Total
Management And General	48548	ManagementAndGeneral

Payments To Affiliates PaymentsToAffiliates

Field	Value	IRS element (for citing)
Total	0	Total

Depreciation Depletion DepreciationDepletion

Field	Value	IRS element (for citing)
Total	132259	Total
Program Services	68422	ProgramServices
Management And General	22031	ManagementAndGeneral
Fundraising	41806	Fundraising

Insurance Insurance

Field	Value	IRS element (for citing)
Total	53876	Total
Program Services	42837	ProgramServices
Management And General	3225	ManagementAndGeneral
Fundraising	7814	Fundraising

Other Expenses OtherExpenses (5 entries)

DescriptionDescription	TotalTotal	FundraisingFundraising	Program ServicesProgramServices	Management And GeneralManagementAndGeneral
CREDIT CARD & BROKERAGE FEES	186625	186625
OTHER SPECIAL EVENTS EXPENSE	681038	681038
DONATION PROCESSING	94951	94951
MARATHON RUNNER FEES	101964	101964
DUES AND SUBSCRIPTIONS	38693	9551	22535	6607

All Other Expenses AllOtherExpenses

Field	Value	IRS element (for citing)
Total	29665	Total
Program Services	5057	ProgramServices
Management And General	4985	ManagementAndGeneral
Fundraising	19623	Fundraising

Total Functional Expenses TotalFunctionalExpenses

Field	Value	IRS element (for citing)
Total	60056544	Total
Program Services	54545702	ProgramServices
Management And General	1373278	ManagementAndGeneral
Fundraising	4137564	Fundraising

Cash Non Interest Bearing CashNonInterestBearing

Field	Value	IRS element (for citing)
BOY	4579	BOY
EOY	1724	EOY

Savings And Temp Cash Investments SavingsAndTempCashInvestments

Field	Value	IRS element (for citing)
BOY	16253619	BOY
EOY	47584331	EOY

Pledges And Grants Receivable PledgesAndGrantsReceivable

Field	Value	IRS element (for citing)
BOY	35167945	BOY
EOY	28467039	EOY

Field	Value	IRS element (for citing)
Accounts Receivable		AccountsReceivable

Inventories For Sale Or Use InventoriesForSaleOrUse

Field	Value	IRS element (for citing)
BOY	28036	BOY
EOY	22872	EOY

Prepaid Expenses Deferred Charges PrepaidExpensesDeferredCharges

Field	Value	IRS element (for citing)
BOY	156687	BOY
EOY	310926	EOY

Field	Value	IRS element (for citing)
Land Buildings Equipment Basis	1220999	LandBuildingsEquipmentBasis
Land Bldg Equipment Accum Deprec	883939	LandBldgEquipmentAccumDeprec

Land Buildings Equipment Basis Net LandBuildingsEquipmentBasisNet

Field	Value	IRS element (for citing)
BOY	278893	BOY
EOY	337060	EOY

Investments Pub Traded Securities InvestmentsPubTradedSecurities

Field	Value	IRS element (for citing)
BOY	17091145	BOY
EOY	1467886	EOY

Other Assets Total OtherAssetsTotal

Field	Value	IRS element (for citing)
BOY	33061	BOY
EOY	33061	EOY

Total Assets TotalAssets

Field	Value	IRS element (for citing)
BOY	69013965	BOY
EOY	78224899	EOY

Accounts Payable Accrued Expenses AccountsPayableAccruedExpenses

Field	Value	IRS element (for citing)
BOY	1768622	BOY
EOY	1542594	EOY

Grants Payable GrantsPayable

Field	Value	IRS element (for citing)
BOY	41763613	BOY
EOY	53453069	EOY

Unsecured Notes Loans Payable UnsecuredNotesLoansPayable

Field	Value	IRS element (for citing)
BOY	1000196	BOY
EOY	1000196	EOY

Other Liabilities OtherLiabilities

Field	Value	IRS element (for citing)
BOY	453533	BOY
EOY	626588	EOY

Total Liabilities TotalLiabilities

Field	Value	IRS element (for citing)
BOY	44985964	BOY
EOY	56622447	EOY

Field	Value	IRS element (for citing)
Follow SFAS117	X	FollowSFAS117

Unrestricted Net Assets UnrestrictedNetAssets

Field	Value	IRS element (for citing)
BOY	2345986	BOY
EOY	4194131	EOY

Temporarily Restricted Net Assets TemporarilyRestrictedNetAssets

Field	Value	IRS element (for citing)
BOY	21682015	BOY
EOY	17408321	EOY

Total Net Assets Fund Balances TotalNetAssetsFundBalances

Field	Value	IRS element (for citing)
BOY	24028001	BOY
EOY	21602452	EOY

Total Liab Net Assets Fund Balances TotalLiabNetAssetsFundBalances

Field	Value	IRS element (for citing)
BOY	69013965	BOY
EOY	78224899	EOY

Field	Value	IRS element (for citing)
Info In Schedule O Part XI	X	InfoInScheduleOPartXI
Reconcilation Revenue Expenses	-2435084	ReconcilationRevenueExpenses
Reconcilation Other Changes	9535	ReconcilationOtherChanges
Method Of Accounting Accrual	X	MethodOfAccountingAccrual
Accountant Compile Or Review	false	AccountantCompileOrReview
FS Audited	true	FSAudited
Audit Committee	true	AuditCommittee
Financial Statement Consolidated	X	FinancialStatementConsolidated
Federal Grant Audit Required	false	FederalGrantAuditRequired

Schedule A IRS990ScheduleA

Field	Value	IRS element (for citing)
Publicly Supported Org170b1 Avi	X	PubliclySupportedOrg170b1Avi

Gifts Grants Contrib Received170 GiftsGrantsContribReceived170

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	31063349	CurrentTaxYearMinus4Years
Current Tax Year Minus3 Years	37700456	CurrentTaxYearMinus3Years
Current Tax Year Minus2 Years	42077867	CurrentTaxYearMinus2Years
Current Tax Year Minus1 Year	51259577	CurrentTaxYearMinus1Year
Current Tax Year	57125384	CurrentTaxYear
Total	219226633	Total

Total170 Total170

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	31063349	CurrentTaxYearMinus4Years
Current Tax Year Minus3 Years	37700456	CurrentTaxYearMinus3Years
Current Tax Year Minus2 Years	42077867	CurrentTaxYearMinus2Years
Current Tax Year Minus1 Year	51259577	CurrentTaxYearMinus1Year
Current Tax Year	57125384	CurrentTaxYear
Total	219226633	Total

Field	Value	IRS element (for citing)
Amounts Subst Contributors Total	75581258	AmountsSubstContributorsTotal
Public Support Total170	143645375	PublicSupportTotal170

Gross Investment Income170 GrossInvestmentIncome170

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	393477	CurrentTaxYearMinus4Years
Current Tax Year Minus3 Years	764390	CurrentTaxYearMinus3Years
Current Tax Year Minus2 Years	744930	CurrentTaxYearMinus2Years
Current Tax Year Minus1 Year	157415	CurrentTaxYearMinus1Year
Current Tax Year	232554	CurrentTaxYear
Total	2292766	Total

Other Income170 OtherIncome170

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	58519	CurrentTaxYearMinus4Years
Current Tax Year Minus3 Years	117	CurrentTaxYearMinus3Years
Current Tax Year Minus2 Years	25682	CurrentTaxYearMinus2Years
Current Tax Year Minus1 Year	15213	CurrentTaxYearMinus1Year
Current Tax Year	34177	CurrentTaxYear
Total	133708	Total

Field	Value	IRS element (for citing)
Total Support	221653107	TotalSupport
Public Support Pertcentage170	0.64806	PublicSupportPertcentage170
Public Support Pertcent Prior Year	0.69221	PublicSupportPertcentPriorYear
Thirty Three Percnt Tests CY170	X	ThirtyThreePercntTestsCY170

Schedule B IRS990ScheduleB

Contributor Info ContributorInfo

Field	Value	IRS element (for citing)
Contributor Number	RESTRICTED	ContributorNumber

Contributor Name Business ContributorNameBusiness

Field	Value	IRS element (for citing)
Business Name Line1	RESTRICTED	BusinessNameLine1

Contributor Address US ContributorAddressUS

Field	Value	IRS element (for citing)
Address Line1	RESTRICTED	AddressLine1
Address Line2	RESTRICTED	AddressLine2
City	RESTRICTED	City
State	RESTRICTED	State
ZIP Code	RESTRICTED	ZIPCode

Field	Value	IRS element (for citing)
Aggregate Contributions	RESTRICTED	AggregateContributions

Schedule D IRS990ScheduleD

Field	Value	IRS element (for citing)
Art Public Exhibition Amts		ArtPublicExhibitionAmts
Held Works Of Art Amts		HeldWorksOfArtAmts
Land		Land
Buildings		Buildings

Leasehold Improvements LeaseholdImprovements

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	304571	OtherCostOrOtherBasis
Depreciation	155482	Depreciation
Book Value	149089	BookValue

Equipment Equipment

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	683445	OtherCostOrOtherBasis
Depreciation	0	Depreciation
Book Value	103619	BookValue

Other Land Buildings OtherLandBuildings

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	232983	OtherCostOrOtherBasis
Depreciation	0	Depreciation
Book Value	84352	BookValue

Field	Value	IRS element (for citing)
Total Of Book Value Land Buildings	337060	TotalOfBookValueLandBuildings
Federal Income Tax Liability	0	FederalIncomeTaxLiability

Other Liabilities OtherLiabilities (3 entries)

DescriptionDescription	AmountAmount
DEFERRED RENT	$349,036
DUE TO MJFF CANADA	$169,493
INTEREST PAYABLE	$108,059

Field	Value	IRS element (for citing)
Total Of Amounts	626588	TotalOfAmounts
Total Revenue	57621460	TotalRevenue
Total Expenses	60056544	TotalExpenses
Excess Or Deficit For Year	-2435084	ExcessOrDeficitForYear
Net Unrealized GL On Investments	-4743	NetUnrealizedGLOnInvestments
Total Adjustments	-4743	TotalAdjustments
Excess Or Deficit Per FS	-2439827	ExcessOrDeficitPerFS
Tot Revenue Etc Audited Fincl Stmt	57630995	TotRevenueEtcAuditedFinclStmt
Net Unrealized Gains Investments	-4743	NetUnrealizedGainsInvestments
Other Revenues	14278	OtherRevenues
Revenue Not Rptd F990	9535	RevenueNotRptdF990
Revenue Subtotal	57621460	RevenueSubtotal
Total Revenue Per Form990	57621460	TotalRevenuePerForm990
Tot Expenses Etc Audited Fincl Stmt	60070822	TotExpensesEtcAuditedFinclStmt
Other Expenses Included	14278	OtherExpensesIncluded
Expenses Not Rptd F990	14278	ExpensesNotRptdF990
Expenses Subtotal	60056544	ExpensesSubtotal
Total Expenses Per Form990	60056544	TotalExpensesPerForm990

Form990 Schedule D Part XIV Form990ScheduleDPartXIV (2 entries)

IdentifierIdentifier	Return ReferenceReturnReference	ExplanationExplanation
Scheduel D, Page 3, Question 2:	ASC 740-10-05 Footnote	Income taxes: The Foundation is subject to the provisions of the Financial Accounting Standards Board's Accounting Standards Codification ("ASC") 740-10-05 relating to accounting and reporting for uncertainty in income taxes. For the Foundation, ASC 740-10-05 is potentially applicable to the incurrence of unrelated business income ("UBIT") attributable to certain of the Foundation's merchandise sales. The adoption of ASC 740-10-05 has not had, and is not expected to have, a material impact on the Foundation's financial statements.
RECONCILIATION OF EXPENSES	SCHEDULE D, PART XIII, LINE 2D, PAGE 4	EXPENSES ATTRIBUTABLE TO THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH'S CANADIAN ENTITY.

Schedule F IRS990ScheduleF

Field	Value	IRS element (for citing)
Grant Records Maintained	true	GrantRecordsMaintained

Accts Actvs Out US Table AcctsActvsOutUSTable (5 entries)

RegionRegion	Type Of Activities ConductedTypeOfActivitiesConducted	Total ExpendituresTotalExpenditures
East Asia and the Pacific	Grantmaking	1303250
Europe (Including Iceland and Greenland)	Grantmaking	9803216
Middle East and North Africa	Grantmaking	1241267
North America	Grantmaking	4318064
South America	Grantmaking	125000

Field	Value	IRS element (for citing)
Subtotal Number Of Offices	0	SubtotalNumberOfOffices
Subtotal Number Of Employees	0	SubtotalNumberOfEmployees
Total Number Of Offices	0	TotalNumberOfOffices
Total Number Of Employees	0	TotalNumberOfEmployees
Subtotal Amount Spent	16790797	SubtotalAmountSpent
Total Amount Spent	16790797	TotalAmountSpent

Grants To Orgs Outside US GrantsToOrgsOutsideUS (62 entries)

RegionRegion	Purpose Of GrantPurposeOfGrant	Amount Of Cash GrantAmountOfCashGrant
Europe/Iceland/Greenland	Phase II, randomized, double-blind, placebo-controlled, parallel group, multicentre study to evaluate the safety, tolerability and efficacy of ADX48621 in the treatment of moderate to severe L-dopa induced dyskinesia in patients with Parkinson's disease	900000
Europe/Iceland/Greenland	AFFITOPE based immunotherapeutic strategies for Parkinson?s disease	475000
North America	Testing of davunetide for intranasal administration in mice overexpressing alpha--synuclein	625535
Europe/Iceland/Greenland	A Phase IIa, Multi-Centre, Double-Blind, Randomised, Placebo-Controlled, Parallel Group 12-Month Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of AZD3241 in Patients with Multiple System Atrophy	500000
East Asia/Pacific	Genetic and Environmental Modifiers for LRRK2 Associated PD	624250
East Asia/Pacific	Resting state fMRI as a Biomarker for Parkinson's Disease	75000
Europe/Iceland/Greenland	Diversity Panel profiling of the LRRK2-IN1 compound	9757
North America	Functional Genomic Screening to Identify Novel Regulators of Parkinson's	74772
East Asia/Pacific	Optimization of the ELISA for oxidized DJ-1	125000
Europe/Iceland/Greenland	Validation of enzymatic activity and neuropathology in G2019S LRRK2-induced dopaminergic neurodegeneration in a rat model of Parkinson's disease	308425
Europe/Iceland/Greenland	Investigation of PDE10a Inhibitors for Parkinsons Disease. PI is Bart Ellenbroek.	196515
Europe/Iceland/Greenland	In Vivo Assessment of Alpha-Synuclein Secretion	150000
Europe/Iceland/Greenland	Lamp-2a as a therapeutic traget in Parkinson's Disease	125000
Europe/Iceland/Greenland	Selective neuroprotective effects of the S18Y polymorphic variant of UCH-L1	37500
Europe/Iceland/Greenland	Modulation of the Rho Kinase pathway for improvement of regeneration in PD	248215
Middle East/North Africa	Susceptibility genes for antipsychotic-induced extrapyramidal symptoms as modifier genes in Parkinson's disease and L-dopa treatment response	74998
Europe/Iceland/Greenland	ASAP study: ASymptomatic LRRK2 mutation carriers and Assessment of factors influencing LRRK2-related PD expression study	745168
Europe/Iceland/Greenland	PPMI Clinical Site	257031
Europe/Iceland/Greenland	NeuroEPIC Parkinson's disease study	150000
Europe/Iceland/Greenland	Deciphering the molecular effects of alpha-synuclein in the nucleus: DNA binding and transcriptional dysregulation	74800
Europe/Iceland/Greenland	mTORC1 as a target for the treatment of L-DOPA-induced dyskinesia	249875
Europe/Iceland/Greenland	Validation of FKBP inhibitors to target alpha-synuclein pathology in rodent brain	202656
Europe/Iceland/Greenland	The Sigma 1 receptor as a target for disease modifying therapies in Parkinson's disease	248406
Europe/Iceland/Greenland	The role of mGluR4 in the modulation of L-DOPA-induced motor performance and dyskinesia in a rat model of Parkinson's disease	193385
Europe/Iceland/Greenland	Proof-of-concept clinical trial on the use of the 5-HT1A/1B partial agonist Eltoprazine for treatment of L-DOPA-induced dyskinesias	101396
Europe/Iceland/Greenland	Development of in vivo models of prion-like transfer of alpha-synuclein	95867
Europe/Iceland/Greenland	Down-regulation of GDNF signaling in the a-synuclein model of PD: implications for the use of GDNF in neuroprotective therapy	75000
Europe/Iceland/Greenland	Determine the structure of Roco family proteins	74999
North America	Intermittent Bilateral Intraputamenal Treatment with GDNF	2100000
Europe/Iceland/Greenland	Flibanserin in Levodopa-induced Dyskinesia: MPTP-lesioned Pre-clinical Model	162250
East Asia/Pacific	Nasal PD Treatment-Proof-of-Concept	75000
Middle East/North Africa	Maintenance of continuous plasma levodopa levels through continuous subcutaneous carbidopa administration	1000000
North America	Delayed Start Assessment of Progranulin in a Progressive Rodent Model of Parkinson?s Disease	113630
Europe/Iceland/Greenland	The Trondheim LRRK2 cohort program	199875
East Asia/Pacific	MJFF-Elan Partnership - OzGene Mouse Generation	64500
Europe/Iceland/Greenland	PPMI Clinical Trial Site	257031
Europe/Iceland/Greenland	Laboratory phenotyping of Parkinson disease subjects using a multiplex approach	249894
Europe/Iceland/Greenland	Ghrelin - a peripheral, preclinical biomarker for Parkinson's disease (PD)	216250
Middle East/North Africa	Clinical Assessment of Patients with PD Who Underwent DAT Scan and FDG PET at the Early Stages of Their Extra-Pyramidal Disorder as Part of Their Initial Workup	91670
Middle East/North Africa	Biofeedback-based motor learning to ameliorate freezing of gait	74599
Europe/Iceland/Greenland	The role of LRRK2 in Wnt signaling in vivo	97896
Europe/Iceland/Greenland	Is glucose metabolism perturbed in PD?	50100
Europe/Iceland/Greenland	Biochemical characterization of full length human recombinant LRRK1 and LRRK2 - supplemental funding	200000
Europe/Iceland/Greenland	Coordinated reset (CR) stimulation of the subthalamic nucleus in the MPTP non-human primate model: Target validation for translating into a clinical trial in PD patients	128810
Europe/Iceland/Greenland	Langston Award 2010	25000
North America	Increased dopamine turnover as a manifestation of LRRK2 mutation	395105
North America	LRRK2 G2019S disease penetrance modifiers	262066
North America	Multi-tracer positron emission tomography (PET) functional imaging as a tool to assess the relevance of rodent LRRK2 models to the human neurochemical phenotype associated with LRRK2 mutations related Parkinsonism	259416
North America	The Role of LRRK2 in Neurotransmission	162564
South America	Targeting the Unfolded Protein Response (UPR) transcription factor XBP-1 to treat Parkinson's disease.	125000
Europe/Iceland/Greenland	Exploiting Ser910/935 phosphorylation and 14-3-3 binding to develop biomarkers for LRRK2 activity	193750
Europe/Iceland/Greenland	CDNF (Cerebral Dopamine Neurotrophic Factor) for therapy of Parkinson's disease	515086
Europe/Iceland/Greenland	PPMI Clinical Trial Site	257031
North America	INCREASED DOPAMINE TRANSPORTER FUNCTION AS AN EARLY PHENOTYPE OF PD, PRIOR TO DOPAMINE NEURON CELL DEATH	74976
North America	Functional Analysis of LRRK2: Focus on autophagy	250000
Europe/Iceland/Greenland	CSF LYSOSOMAL HYDROLASES' ACTIVITY AS POSSIBLE MARKER OF PARKINSON'S DISEASE	75000
Europe/Iceland/Greenland	Prospective validation of risk markers for the development of Parkinson's disease	491132
Europe/Iceland/Greenland	Macrophage Precursors as Biomarker for LRRK2-associated Parkinson disease	395000
Europe/Iceland/Greenland	Longitudinal Follow up of clinical and neuroimaging signs as well as biomarkers in symptomatic and asymptomatic LRRK2 mtuation carriers in comparison to indiopathic PD and controls	382500
Europe/Iceland/Greenland	PPMI Clinical Trial Site	257031
Europe/Iceland/Greenland	Immuno-PCR detection of alpha-synuclein phosphorylated at serine-129 as PD biomarker	155785
Europe/Iceland/Greenland	Genetic-epidemiological confirmation of top hits of GWAS of Parkinson disease: A large multi-center collaborative study.	74800

Field	Value	IRS element (for citing)
Total Number Of501c3 Orgs	50	TotalNumberOf501c3Orgs
Total Number Of Other Orgs	12	TotalNumberOfOtherOrgs
Transfer To Foreign Corp	false	TransferToForeignCorp
Interest In Foreign Trust	false	InterestInForeignTrust
Own Foreign Corp	false	OwnForeignCorp
Passive Foreign Invest Co	false	PassiveForeignInvestCo
Foreign Partnership	false	ForeignPartnership
Boycott Countries	false	BoycottCountries

Form990 Schedule F Part V Form990ScheduleFPartV

Field	Value	IRS element (for citing)
Identifier	SCHEDULE F	Identifier
Return Reference	PROCEDURES FOR MONITORING GRANT FUNDS OUTSIDE THE UNITED STATES:	ReturnReference
Explanation	THE FOUNDATION AWARDS RESEARCH GRANTS BASED UPON THE GUIDANCE AND INPUT OF THE SCIENTIFIC ADVISORY BOARD AND OTHER HIGHLY REGARDED SCIENTISTS WHO SERVE ON GRANT REVIEW COMMITTEES SPECIALIZING IN PARKINSON'S RESEARCH. Goals and milestones are described within each grant award. Most Grant awards are allocated in multiple payments with key benchmarks set at the time of the grant award. MJFF's Research team closely monitors the progress of each grant awarded. There is frequent communication between grantees and MJFF staff regarding the progress of each grant. Progress is verified before additional payments are made.	Explanation

Schedule G IRS990ScheduleG

Field	Value	IRS element (for citing)
Mail Solicitations	X	MailSolicitations
Email Solicitations	X	EmailSolicitations
Solicitation Of Non Govt Grants	X	SolicitationOfNonGovtGrants
Special Fundraising Events	X	SpecialFundraisingEvents
Agreement Ref Fundraising	true	AgreementRefFundraising

Fundraiser Activity Information FundraiserActivityInformation

Field	Value	IRS element (for citing)
Name Of Individual	Event Associates Inc	NameOfIndividual

Address US AddressUS

Field	Value	IRS element (for citing)
Address Line1	162 WEST 56TH STREET 405	AddressLine1
City	NEW YORK	City
State	NY	State
ZIP Code	10019	ZIPCode

Field	Value	IRS element (for citing)
Activity	Fundraising Consultants	Activity
Fundraiser Control Of Funds	false	FundraiserControlOfFunds
Gross Receipts	0	GrossReceipts
Amount Retained By Contractor	49600	AmountRetainedByContractor
Net To Organization	0	NetToOrganization

Field	Value	IRS element (for citing)
Total Gross Receipts	0	TotalGrossReceipts
Total Retained By Contractors	49600	TotalRetainedByContractors
Total Net To Organization	0	TotalNetToOrganization
Licensed States	AL	LicensedStates
Licensed States	AK	LicensedStates
Licensed States	AZ	LicensedStates
Licensed States	AR	LicensedStates
Licensed States	CA	LicensedStates
Licensed States	CO	LicensedStates
Licensed States	CT	LicensedStates
Licensed States	FL	LicensedStates
Licensed States	GA	LicensedStates
Licensed States	IL	LicensedStates
Licensed States	KS	LicensedStates
Licensed States	KY	LicensedStates
Licensed States	ME	LicensedStates
Licensed States	MD	LicensedStates
Licensed States	MA	LicensedStates
Licensed States	MI	LicensedStates
Licensed States	MN	LicensedStates
Licensed States	MS	LicensedStates
Licensed States	NH	LicensedStates
Licensed States	NJ	LicensedStates
Licensed States	NM	LicensedStates
Licensed States	NY	LicensedStates
Licensed States	NC	LicensedStates
Licensed States	ND	LicensedStates
Licensed States	OH	LicensedStates
Licensed States	OK	LicensedStates
Licensed States	OR	LicensedStates
Licensed States	PA	LicensedStates
Licensed States	RI	LicensedStates
Licensed States	SC	LicensedStates
Licensed States	TN	LicensedStates
Licensed States	UT	LicensedStates
Licensed States	VA	LicensedStates
Licensed States	WA	LicensedStates
Licensed States	WV	LicensedStates
Licensed States	WI	LicensedStates

Events Information EventsInformation

Field	Value	IRS element (for citing)
Name Of Event1	FUNNY THING	NameOfEvent1
Gross Receipts Event1	4692806	GrossReceiptsEvent1
Charitable Contributions Event1	4481056	CharitableContributionsEvent1
Gross Revenue Event1	211750	GrossRevenueEvent1
Other Direct Expenses Event1	211750	OtherDirectExpensesEvent1
Name Of Event2	SUNNY THING	NameOfEvent2
Gross Receipts Event2	875650	GrossReceiptsEvent2
Charitable Contributions Event2	823400	CharitableContributionsEvent2
Gross Revenue Event2	52250	GrossRevenueEvent2
Other Direct Expenses Event2	52250	OtherDirectExpensesEvent2
Total Number Of Other Events	3	TotalNumberOfOtherEvents
Gross Receipts Other Events	1778361	GrossReceiptsOtherEvents
Charitable Contrib Other Events	1683821	CharitableContribOtherEvents
Gross Revenue Other Events	94540	GrossRevenueOtherEvents
Other Direct Expenses Other Events	94540	OtherDirectExpensesOtherEvents
Gross Receipts Total	7346817	GrossReceiptsTotal
Charitable Contributions Total	6988277	CharitableContributionsTotal
Gross Revenue Total Events	358540	GrossRevenueTotalEvents
Other Direct Expenses Total Events	358540	OtherDirectExpensesTotalEvents
Direct Expense Summary Events	358540	DirectExpenseSummaryEvents

Schedule I IRS990ScheduleI

Field	Value	IRS element (for citing)
Records Maintained	true	RecordsMaintained

Recipient Table RecipientTable (161 entries)

Address Line1AddressUS/AddressLine1	CityAddressUS/City	StateAddressUS/State	ZIP CodeAddressUS/ZIPCode	EIN Of RecipientEINOfRecipient	Amount Of Cash GrantAmountOfCashGrant	Purpose Of GrantPurposeOfGrant	IRC SectionIRCSection
Acadia Pharmaceuticals
3911 Sorrento Valley Blvd	San Diego	CA	92121	061376651	301015	Development of Nurr1-RXR heterodimer selective ago agonists for Parkinson's disease
Adolor Corporation
700 Pennsylvania Drive	Exton	PA	19341	311429198	363400	Optimization of MOR Antagonists for the Treatment of L-DOPA-Induced Dyskinesias in Parkinson's Disease
Amarantus Therapeutics Inc
675 Almanor Avenue	Sunnyvale	CA	94085	261758388	370717	Comparison and Actions of MANF and GDNF in Rodent Models of Parkinson's Disease
Amicus Therapeutics
6 Cedar Brook Drive	Cranbury	NJ	08512	710869350	499503	Use of the orally administered pharmacological cha chaperone AT3375 to reduce alpha-synuclein levels in the brain of Thy-1 alpha-synuclein mice
Arizona State University
1711 S Rural Road Box 6006	Tempe	AZ	85287	019669600	552273	Morphology specific anti-synuclein nanobodies as t therapeutics for PD	501(C)(3)
Arizona State University
1711 S Rural Road Box 6006	Tempe	AZ	85287	019669600	156251	Identifying and localizing toxic oligomeric a-syn with morphology specific nanobodies	501(C)(3)
Arizona State University
1711 S Rural Road Box 6006	Tempe	AZ	85287	019669600	110000	In vivo SPECT Imaging of synuclein aggregation wit with morphology specific antibody based ligands	501(C)(3)
Athersys Inc
3201 Carnegie Avenue	Cleveland	OH	44115	341830213	140590	Development of an Adult Adherent Allogeneic Stem C Cell Product for Treatment of Parkinson's Disease
Avid Radiopharmaceuticals Inc
3711 Market Street	Philadelphia	PA	19104	201811104	493438	18F-labeled alpha-synuclein ligands for PET imagin imaging of Lewy bodies
Baylor College of Medicine
The Smith Tower	Houston	TX	77030	741613878	257031	PPMI Clinical Trial Site	501(C)(3)
Beth Israel Deaconess Medical Center
330 Brookline Ave	Boston	MA	02445	042103881	100000	PGC-1 Alpha as a Neuroprotective Target in Parkins Parkinson's Disease	501(C)(3)
Beth Israel Medical Center
10 Union Square East	New York	NY	10003	135564934	14270	Parkinson's Disease, Ashkenazi Jews and LRRK2: a c consortium proposal - SUPPLEMENT	501(C)(3)
Biomer Technology
1047 Serpentine Lane Bldg 200	San Diego	CA	94566		6865	Generation of LRRK2 phospho-peptides
Board of Regents of the University of Wisconsin Sy
1415 Engineering Drive	Madison	WI	53706	396006492	187476	Novel Antibodies for the Delivery of Parkinson's T Therapeutics	501(C)(3)
Board of Regents of the University of Wisconsin Sy
1111 Highland Avenue	Madison	WI	53705	396006492	90157	Mechanism and Modulation of Alpha-Synuclein Expres Expression	501(C)(3)
Boston University
715 Albany St	Boston	MA	02118	042103545	257031	PPMI Clinical Trial Site	501(C)(3)
CalAsia Pharmaceuticals Inc
11494 Sorrento Valley Road	San Diego	CA	92121	270641400	549882	Novel, selective and potent brain-penetrant small molecule inhibitors of cytosolic Hsp90
Case Western Reserve University
2103 Cornell Road	Cleveland	OH	44106	341018992	221634	Supplement-Characterization of LRRK2 cellular and signaling pathways	501(C)(3)
Ceregene Inc
9381 Judicial Drive Suite 130	San Diego	CA	92121	954838818	2500000	A Sham- Surgery Controlled Phase 2 Trial Testing A AAV2-neurturin (CERE-120) in Moderately Advanced Parkinson Disease
Coriell Institute for Medical Research
403 Haddon Avenue	Camden	NJ	08103	210672684	730709	PPMI 2010: BioRepository	501(C)(3)
Cortex Pharmaceuticals Inc
15231 Barranca Parkway	Irvine	CA	92618	330303583	384849	Assessment of the Neurorestorative Potential of En Enhanced Neurotrophic Support via Positive Glutamatergic Modulation in the MPTP Mouse Model of PD
Cortex Pharmaceuticals Inc
15231 Barranca Parkway	Irvine	CA	92618	330303583	7177	Assessment of the Neurorestorative Potential of En Enhanced Neurotrophic Support via Positive Glutamatergic Modulation in the MPTP Mouse Model of PD-Supplement
Covance
8211 SciCor Drive	Indianapolis	IN	46214	223265977	388784	PPMI Clinical Laboratory Analysis, PPMI study 001 001
Covance
180 Rustcraft Road	Indianapolis	IN	02026	223265977	155000	Covance LRRK2 ELISA - Using Invitrogen LRRK2 Fragm Fragment, 5 MJFF Epitomics Antibodies, and 1 Neuromab Antibody
Covance
180 Rustcraft Road	Dedham	MA	02026	223265977	59580	DJ-1 analysis in qualification study
Covance
180 Rustcraft Road	Indianapolis	IN	02026	223265977	25000	DJ-1 Reproducibility & Year 1 Analyses in PPMI.
Covance
180 Rustcraft Road	Indianapolis	IN	02026	223265977	16280	Hemoglobin Analysis in Qualification Study
Covance
180 Rustcraft Road	Dedham	MA	02026	223265977	9000	Purification of novel alpha-synuclein polyclonal a antibodies
Covance
180 Rustcraft Road	Burlingame	CA	02026	223265977	6000	Assay optimization to determine suitability of rab rabbit monoclonal antibodies
Covance
5858 Horton St Suite 500	Emeryville	CA	94608	223265977	5777	Qualification Study - Covance handling of specimen specimens and running ELISA-PPMI prep
Covance
180 Rustcraft Road	Indianapolis	IN	02026	223265977	5640	Covance Protein BCA Analysis
Depomed Inc
1360 OBrien Dr	Menlo Park	CA	94025	943329046	150000	Study to Compare Levodopa/Carbidopa Safety, Tolera Tolerability, Pharmacokinetics and Pharmacodynamics following Administration of Gastric Retentive Extended-Release Tablets versus a Reference Extended-Release Tablet in Parkinson's Disease Patients
Edmond and Lily Safra International Institute of N
Prof Francisco Luciano de Oliveira	Durham	NC	59066		236498	Validation of Dorsal Column Electrical Stimulation Stimulation as a Target for Parkinson's Disease Therapy in 6-OHDA Non-human Primates	501(C)(3)
Emerald BioStructures
7869 NE Day Road West	Bainbridge Island	WA	98110	911821586	909863	Determine the structure of LRRK2 protein
Emerald BioStructures
7869 NE Day Road West	Bainbridge Island	WA	98110	911821586	25000	PINK1 Protein Generation
Emory University
1841 Clifton Road Third Floor	Atlanta	GA	30329	580566256	257031	PPMI Clinical Trial Site	501(C)(3)
Epitomics
863 Mitten Road Suite 103	Burlingame	CA	94010		166678	LRRK2 Phospho-specific Polyclonal Antibody Generat Generation
Epitomics
863 Mitten Road	Burlingame	CA	94010		64352	LRRK2 rabbit monoclona antibody supplement - scale scale up
Epitomics
863 Mitten Road Suite 103	Burlingame	CA	94010		30872	PINK1 monoclonal rabbit antibody generation FormPI Formerly: Zou and Chen
Epitomics
863 Mitten Road Suite 103	Burlingame	CA	94010		11325	LRRK2 rabbit monoclonal antibody supplement - addi additional aliquotting and shipping of the LRRK2 antibodies- Formerly: Zou and Chen
Gardedam Therapeutics
651 Forest Avenue	Palo Alto	CA	94301	273699049	75000	Identification of small-molecule stabilizers of DJ DJ-1: biophysical and cellular validation
Georgetown University
3970 Reservoir Road	Washington	DC	20057	530196603	74249	SNCA haplotyping in Parkinson's disease and multip multiple system atrophy	501(C)(3)
Harbor Biosciences
4435 Eastgate Mall	San Diego	CA	92121	133697002	146279	HE3286 as treatment for Parkinson's disease
Harvard University
250 Longwood Ave	Boston	MA	02115	421035800	575185	Development of selective LRRK2 inhibitors	501(C)(3)
Harvard University
115 Mill Street	Belmont	MA	02478	421035800	294899	Patient-specific iPS cell-derived neurons and dise disease-associated LRRK2 mutations for Parkinson's disease research	501(C)(3)
Harvard University
77 Avenue Louis Pasteur	Boston	MA	02115	421035800	200000	Physiological and Pathological Implications of the the Unique Subcellular Distribution of LRRK2	501(C)(3)
Harvard University
240 Longwood Ave	Boston	MA	02115	421035800	124898	Does the Ubiquitin Ligase, Nedd4, Protect Against Alpha-Synucleinopathy?	501(C)(3)
Health Advances LLC
9 Riverside Road	Watertown	MA	02493	111111111	15000	Industry Landscape Update
Indiana University
410 West Tenth Street	Indianapolis	IN	46202	356001673	499819	PROGENI Family Study	501(C)(3)
Invitrogen Corporation
501 Charmany Drive	Sunnyvale	CA	53719	330373077	72400	LRRK2 Biochemical Studies (Invitrogen/Nichols Coll Collaboration)"
Johns Hopkins University
600 North Wolfe St	Baltimore	MD	21287	520595110	257031	PPMI Clinical Trial Site	501(C)(3)
Johns Hopkins University
School of Medicine	Baltimore	MD	21205	520595110	75000	Identification and Validation of the modifiers of LRRK2-induced toxicity	501(C)(3)
Massachusetts General Hospital
114 16th St	Charlestown	MA	02129	042697983	249043	Development and screening of contrast agents for i in vivo imaging of Parkinson's Disease	501(C)(3)
Massachusetts General Hospital
114 16th Street	Charlestown	MA	02129	042697983	127324	Generation and characterization of iPS neurons fro from PINK1- and Parkin-linked Parkinson's disease	501(C)(3)
Massachusetts General Hospital
114 Sixteenth Street	Charlestown	MA	02129	042697983	77329	Oligomeric equilibrium in male and female brains w with alpha-synuclein pathology	501(C)(3)
Mayo Clinic
4500 San Pablo Road South	Jacksonville	FL	32224	593337028	229128	Global estimates for the role of LRRK2 variation i in Parkinsons disease susceptibility	501(C)(3)
Mayo Clinic
13400 E Shea Blvd	Jacksonville	FL	85259	593337028	25000	Compensation to Dr Adler re Novel Hypotheses in PC PD program	501(C)(3)
McLean Hospital
115 Mill Street	Belmont	MA	02478	042697981	255173	Neuroprotective efficacy of RAB3B in animal models models of alpha-synucleinopathy	501(C)(3)
McLean Hospital
115 Mill Street	Belmont	MA	02478	042697981	132603	Gait disturbances in Parkinson's disease: new link links to alpha-synuclein pathology	501(C)(3)
Mount Sinai School of Medicine
One Gustave L Levy Place	New York	NY	10029	136171197	400000	Determining pharmacodynamic biomarkers of LRRK2 ac activity in lymphocytes	501(C)(3)
Mount Sinai School of Medicine
One Gustave L Levy Place	New York	NY	10029	136171197	262818	LRRK2 Effects on Neural Differentiation	501(C)(3)
National Institute on Aging
35 Convent Drive	Bethesda	MD	20892	522038294	34375	Biochemical characterization of full length human recombinant LRRK1 and LRRK2	501(C)(3)
National Institute on Drug Abuse (NIDA)NIH
251 Bayview Blvd	Baltimore	MD	21224		75000	Dopamine D1-D3 receptor heteromer as a new target for Parkinson's disease	501(C)(3)
Neuraltus Pharmaceuticals Inc
2483 E Bayshore Rd Suite 212	Palo Alto	CA	94303	201008507	167361	Targeting alpha-synuclein-lipid interactions in pr preclinical Parkinson's disease models.
Neuroscience Associates
10915 Lake Ridge Drive	Knoxville	TN	37934	621540123	349188	Lrrk2 mouse characterization (histology)
Neuroscience Associates
10915 Lake Ridge Drive	Knoxville	TN	37934	621540123	245566	KO rat characterization (histology)
Neuroscience Associates
10915 Lake Ridge Drive	Knoxville	TN	37934	621540123	122783	KO rat characterization (histology)-LRRK2
Northeastern University
360 Huntington Avenue	Boston	MA	02115	041679980	375000	Intranasal GDNF for Parkinson's Disease: Next SteI Steps in Preclinical Development	501(C)(3)
Northern California Institute for Research & Educa
4150 Clement St 114M	San Francisco	CA	94121	943084159	110689	PPMI - 2010 - DTI Core	501(C)(3)
Northwestern University
710 North Lake Shore Drive	Chicago	IL	60611	362167817	257031	PPMI Clinical Trial Site	501(C)(3)
Northwestern University
303 E Superior St	Chicago	IL	60611	362167817	74762	Genetic dissection of Parkinson's disease vulnerab vulnerable dopaminergic neurons population	501(C)(3)
Northwestern University
710 North Lake Shore Drive	Chicago	IL	60611	362167817	58885	A Pilot Phase II Double-Blind, Placebo-Controlled, Placebo-Controlled, Dosage Finding and Tolerability Study of Isradipine as a Disease Modifying Agent in Patients With Early Parkinson's Disease	501(C)(3)
Omeros Corporation
1420 Fifth Avenue	Seattle	WA	98101	911663741	76442	Selective inhibition of cyclic nucleotide phosphod phosphodiesterase type 7 (PDE7): A novel and efficacious approach to treating Parkinson's disease
Oregon Health & Science University
3181 SW Sam Jackson Park Rd	Portland	OR	97239	931176109	257031	PPMI Clinical Trial Site	501(C)(3)
Parexel
Glendale Adventist Medical Center	Glendale	CA	91206	043517643	55156	Parexel Qualification Study
PARK IP Translations
134 W 29th Street	New York	NY	10001	208132576	15000	PPMI Pre-Enrollment: Translation Services
Parkinson's Action Network
1025 Vermont Ave NW Suite 1120	Washington	DC	20005	943172675	250000	PAN Funding 2010	501(C)(3)
Pfizer Global Research and Development
Eastern Point Road	Princeton	NJ	06340	141396954	300000	Elucidating the Function and Downstream Targets of of LRKK2
PsychoGenics
765 Old Saw Mill River Road	Tarrytown	NY	10591		150000	Support for your collaboration on 'Proof-of-concep 'Proof-of-concept clinical trial on the use of the 5-HT1A/1B partial agonist Eltoprazine for treatment of L-DOPA-induced dyskinesias. - Linked to Bjorklund CIA 2009
Rush University
1735 W Harrison Str	Chicago	IL	60612	362174823	230025	A rodent model of pathological gambling associated associated with medicated parkinsonian patients.	501(C)(3)
Rush University
1735 West Harrison Street Suite 30	Chicago	IL	60612	362174823	219185	A monkey alphasynuclein model of Parkinson's disea disease	501(C)(3)
Rush University
1735 West Harrison Street Suite 30	Chicago	IL	60612	362174823	74999	Protecting innervation: Nmnat1 gene therapy for Pa Parkinson's disease	501(C)(3)
Saint Jude Children's Research Hospital
332 North Lauderdale	Memphis	TN	38105	162064601	88096	Role of H1N1 influenza virus in the etiology of Pa Parkinson's disease.	501(C)(3)
Saint Jude Children's Research Hospital
332 North Lauderdale	Memphis	TN	38105	162064601	75000	Development of a progressive familial mouse model of Parkinson's disease.	501(C)(3)
Sangamo BioSciences Inc
501 Canal Blvd Suite A100	Richmond	CA	94804	680359556	895257	Development of a Zinc Finger Protein Therapeutic f for the Potential Treatment of Parkinson's Disease
Sigma-Aldrich
2033 Westport Center Drive	St Louis	MO	63146	841656258	49353	Sigma breeding for rat characterization - Non-LRRK Non-LRRK2
Sigma-Aldrich
2033 Westport Center Drive	St Louis	MO	63146	841656258	46850	Generation of KO Rat: LRRK1
Sigma-Aldrich
2033 Westport Center Drive	St Louis	MO	63146	841656258	24676	Sigma breeding for rat characterization- LRRK2
Signum Biosciences
7 Deer Park Drive	Monmouth Junction	NJ	08852	010615746	164625	Targeting alpha-Synuclein Dephosphorylation via PP PP2A Activation as a Novel PD Therapeutic
Signum Biosciences
7 Deer Park Drive	Monmouth Junction	NJ	08852	010615746	128583	Characterization of PP2A as a Novel Therapeutic Ta Target and a Biomarker of PD
SpringBox Ltd
708 Congress Ave	Austin	TX	78701		196930	Fox Trial Finder Discovery and Build Out
Stanford University
318 Campus Drive West	Stanford	CA	94305	941156365	250000	Developing optogenic technology for primates to un understand basal ganglia circuitry	501(C)(3)
Stanford University
269 Campus Drive	Stanford	CA	94305	941156365	103913	Aldehyde Dehydrogenase Activators as Novel Treatme Treatment for Parkinson's disease	501(C)(3)
Sun Health Research Institute
10515 W Santa Fe Drive	Sun City	AZ	85351	860768795	257031	PPMI Clinical Trial Site	501(C)(3)
Sun Health Research Institute
10515 W Santa Fe Drive	Sun City	AZ	85351	860768795	25000	Compensation to Dr Beach re Novel Hypotheses in PD PD program	501(C)(3)
SUNY Downstate Medical Center
450 Clarkson Ave	Brooklyn	NY	11203	141368361	362882	Optimization of optical coherence tomography as a biomarker for Parkinson's disease.	501(C)(3)
Synthonics Inc
1700 Kraft Drive	Blacksburg	VA	24060	203899302	270850	Metal Complexation with Levodopa to Improve Contin Continuous Dopaminergic Stimulation
Taconic
5 Cedar Brook Drive	Cranbury	NJ	08512	330675808	178520	Elan/MJFF Generation & Characterization (Phase 1) MJFF-6/7/8/9-P3520/P3521/P3522/P3523
Taconic
5 Cedar Brook Drive	Cranbury	NJ	08512	330675808	126000	LRRK1 constitutive Gene KO mouse; Dual LRRK1/LRRK2 LRRK1/LRRK2 KO Mouse MJFF4/5-P3518/P3519
Taconic
5 Cedar Brook Drive	Cranbury	NJ	08512	330675808	97150	LRRK2 dead kinase animal model MJFF-10/11/12-P352L MJFF-10/11/12-P3524/P3525/P3526"
Taconic
5 Cedar Brook Drive	Cranbury	NJ	08512	330675808	73673	CJ Li Alpha-Synuclein Rat Housing
Taconic
5 Cedar Brook Drive	Cranbury	NJ	08512	330675808	49115	CJ Li LRRK2 Rat Housing
Texas A&M University
Department of Pathobiology	College Station	TX	77843	742245072	73200	The role of alpha-synuclein in the pathogenesis of of Parkinson's disease in a rat animal model	501(C)(3)
The Bachmann-Strauss Dystonia & Parkinson Foundati
551 Fifth Avenue	New York	NY	10176		10000	Support of Annual Think Tank	501(C)(3)
The Buck Institute for Research on Aging
8001 Redwood Blvd	Novato	CA	94945	943030609	125000	Pharmacological PHD inhibition as a potential PD n neuroprotectant therapy	501(C)(3)
The Burnham Institute for Medical Research
10901 N Torrey Pines Rd	La Jolla	CA	92017	510197108	208250	Quantitative Analysis of S-Nitrosylated Proteins i in Parkinson's Disease	501(C)(3)
The Institute for Neurodegenerative Disorders
60 Temple St Suite 8B	New Haven	CT	06510	061582206	675434	PPMI 2010: Imaging Core	501(C)(3)
The Institute for Neurodegenerative Disorders
60 Temple St Suite 8B	New Haven	CT	06510	061582206	336185	PPMI: Leadership Core 2010	501(C)(3)
The Institute for Neurodegenerative Disorders
60 Temple St Suite 8B	New Haven	CT	06511	061582206	257031	PPMI Clinical Trial Site	501(C)(3)
The Institute for Neurodegenerative Disorders
60 Temple St Suite 8B	New Haven	CT	06510	061582206	15492	PPMI Call Center	501(C)(3)
The Jackson Laboratory
610 Main Street	Bar Harbor	ME	04609	010211513	107315	LRRK2 CJ Li Mouse Characterization Study 20010_BHC 20010_BHCB	501(C)(3)
The Jackson Laboratory
610 Main Street	Bar Harbor	ME	04609	010211513	21000	JAX animal housing project - Cai	501(C)(3)
The Jackson Laboratory
610 Main Street	Bar Harbor	ME	04609	010211513	21000	JAX animal housing project - Yue	501(C)(3)
The Jackson Laboratory
610 Main Street	Bar Harbor	ME	04609	010211513	14000	JAX animal housing project- Cai	501(C)(3)
The Jackson Laboratory
610 Main Street	Bar Harbor	ME	04609	010211513	14000	JAX animal housing project- Richfield	501(C)(3)
The Parkinson's Institute
675 Almanor Avenue	Sunnyvale	CA	94085	943061594	496920	Establishing an LRRK2 Signaling Pathway and Assays for Patient Derived Samples	501(C)(3)
The Parkinson's Institute
675 Almanor Avenue	Sunnyvale	CA	94085	943061594	257031	PPMI Clinical Trial Site	501(C)(3)
The Scripps Research Institute
5353 Parkside Drive	Jupiter	FL	33458	330435954	500000	Probing the Function of SGK1 and its Relationship to LRRK2 and Parkinson?s Disease	501(C)(3)
Thomas Jefferson University
900 Walnut Street	Philadelphia	PA	19107	232829095	100000	Gremlin-1 a putative VTA-derived Neuroprotective Factor in Parkinson's disease	501(C)(3)
Translational Genomics Research Institute
445 N 5th St	Phoenix	AZ	85004	753065445	75000	MicroRNAs as biomarkers for Parkinson's disease; a comparison of CSF and blood	501(C)(3)
Tufts-New England Medical Center
800 Washington Street	Boston	MA	02111		75000	Generation of a Novel Recombinant Protein Activator of GPR88	501(C)(3)
University of Alabama at Birmingham
1719 6th Ave South CIRC 516	Birmingham	AL	35294	600539600	257031	PPMI Clinical Trial Site	501(C)(3)
University of Alabama at Birmingham
1719 6th Ave South CIRC 516	Birmingham	AL	35294	600539600	128243	LRRK2 Dimerization as Pharmacodynamic Biomarkers of Activity	501(C)(3)
University of Alabama at Birmingham
1719 6th Ave South CIRC 516	Birmingham	AL	35294	600539600	39836	Validation of VPS41 and TorsinA as Target for Parkinson Disease Therapy	501(C)(3)
University of Arizona
College of Medicine	Tucson	AZ	85724	742652689	124999	VEGF-B - a new neurotrophic factor for treatment for Parkinson's disease	501(C)(3)
University of British Columbia
3011-950 West 28th Avenue	Jacksonville	FL	11111		75000	Characterization of PARK16	501(C)(3)
University of California Irvine
3238 McGaugh Hall	Irvine	CA	92697	952226406	101250	Anti-amyloid oligomer monoclonal antibodies for treatment of Parkinson's Disease	501(C)(3)
University of California Los Angeles
635 Charles E Young Drive South	Los Angeles	CA	90095	956006143	297793	PPMI 2010: Bioinformatics Core	501(C)(3)
University of California Los Angeles
710 Westwood Plaza	Los Angeles	CA	90095	956006143	250000	Kynurenine 3-monooxygenase (KMO) as a target to develop drugs to block progression of PD.	501(C)(3)
University of California Los Angeles
635 Charles E Young Drive South	Los Angeles	CA	90095	956006143	156306	Bioinformatics Core	501(C)(3)
University of California San Diego
9500 Gilman Drive	La Jolla	CA	92093	952544535	350000	Preclinical study in a PD-like transgenic model of a novel isoindole compound that selectively blocks alpha-synuclein oligomerization	501(C)(3)
University of California San Diego
9500 Gilman Drive	San Diego	CA	92093	952544535	257031	PPMI Clinical Trial Site	501(C)(3)
University of Chicago
5841 S Maryland Avenue MC 2030	Chicago	IL	60637	362177139	77647	Oxidized DJ-1 as a biomarker for Parkinson's disease	501(C)(3)
University of Colorado Denver
12631 East 17th Avenue	Aurora	CO	80045	846000555	477210	Acupuncture as a Symptomatic Treatment for Fatigue in Parkinson's Disease	501(C)(3)
University of Colorado Denver
12700 E 19th Ave	Aurora	CO	80045	846000555	125000	Optimizing metalloporphryins for clinical development	501(C)(3)
University of Florida
100 S Newell Dr	Gainesville	FL	32610	596002052	132777	Regulated rAAV-GDNF to treat Parkinson's disease: Translational research plan	501(C)(3)
University of Iowa
2450 University Capitol Center	Iowa City	IA	52242	426004813	202208	PPMI 2010: Statistics Core	501(C)(3)
University of Michigan
530 Church Street	Ann Arbor	MI	48109	386006309	237242	Treating early cognitive impairments and associated movement control deficits by stimulating alpha4beta2* nAChRs	501(C)(3)
University of Mississippi
2500 N State Street	Jackson	MS	39216	646008520	75000	Increasing Endogenous Neurogenesis Using Neurosteroids: A Novel Therapeutic Strategy to Treat Parkinson's Disease	501(C)(3)
University of Nebraska Medical Center
Nebraska Medical Center	New Haven	CT	68198	470049123	75000	Biomarkers and Immunotherapy for Parkinson's Disease	501(C)(3)
University of Pennsylvania
3400 Spruce Street	Philadelphia	PA	19104	231352685	375506	PPMI 2010: Bioanalytics Core - Full Study	501(C)(3)
University of Pennsylvania
330 South 9th Street	Philadelphia	PA	19104	231352685	257031	PPMI Clinical Trial Site	501(C)(3)
University of Pennsylvania
330 S 9th St	Philadelphia	PA	19107	231352685	8000	PPMI Pre-Enrollment Consulting Fee	501(C)(3)
University of Pittsburgh
3501 Fifth Avenue	Pittsburgh	PA	15260	250965591	31037	Male transgenic rat Parkinson's disease model characterization	501(C)(3)
University of Rochester
1351 Mt Hope Avenue Suite 216	Rochester	NY	14620	263800000	777550	PPMI 2010: Clinical Core
University of Rochester
919 Westfall Road	Rochester	NY	14618	263800000	257031	PPMI Clinical Trial Site	501(C)(3)
University of South Florida
4 Columbia Drive	Tampa	FL	33606	593102112	257031	PPMI Clinical Trial Site	501(C)(3)
University of Texas Health Science Center San Ant
7703 Floyd Curl Drive	San Antonio	TX	78229	741586031	250000	Peroxisome-Proliferator Activated Receptor gamma as a Target for Anti-Dyskinesia Pharmacotherapy	501(C)(3)
University of Utah
295 Chipeta Way	Salt Lake	UT	84108	876000525	47463	Development of a novel zebrafish model to investigate the role of glucocerebrosidase in Parkinson's disease	501(C)(3)
University of Washington
1660 S Columbian Way	Seattle	WA	98108	916001537	257031	PPMI Clinical Trial Site	501(C)(3)
University of Washington
1705 NE Pacific St	Seattle	WA	98195	916001537	15251	Testing whether alpha-synuclein is modified by 4-hydroxy-2-nonenal in the human brain	501(C)(3)
UT Southwestern Medical Center at Dallas (Universi
5323 Harry Hines Blvd	Dallas	TX	75390	756002868	250000	Post-translational modifications of LRRK2	501(C)(3)
Van Andel Research Institute
333 Bostwick Avenue NE	Grand Rapids	MI	49503	522000820	74901	Circulating microRNAs as Biomarkers for Early Detection of Parkinson's Disease	501(C)(3)
Virginia College of Osteopathic Medicine
1861 Pratt Drive	Blacksburg	VA	24060	542052107	144810	Cerium Oxide Nanoparticles in Treatment of Parkinson's Disease.	501(C)(3)
Washington University in St Louis
660 S Euclid	St Louis	MO	63110	430653611	184045	Validation of Neuroimaging Biomarkers for Nigrostriatal Neurons	501(C)(3)
WIL Research Laboratories
1407 George Road	Ashland	OH	44805	260564612	319000	Lrrk2 mouse characterization
WIL Research Laboratories
1407 George Road	Ashland	OH	44805	260564612	248467	KO rat characterization
WIL Research Laboratories
1407 George Road	Ashland	OH	44805	260564612	124233	KO rat characterization-LRRK2
XenoPort
3410 Central Expressway	Santa Clara	CA	95051	943330837	193584	A Novel Prodrug of Acamprosate for Treatment of L-Dopa-Induced Dyskinesias
Zaah Technologies
6 Dubon Court	Jacksonville	FL	11735	680639784	62000	Supplement for database development Clinicogenetic studies of Lrrk2 G2019S in Tunisia
Zymes LLC
777 Terrace Avenue	Hasbrouck Heights	NJ	07604	203153524	476078	Evaluation of the neuroprotectivity ability of Zymes' water-soluble CoQ10 (WS-CoQ10) in animal models of PD; preclinical validation and dose optimization for clinical study

Field	Value	IRS element (for citing)
Total Nbr Of501 C3 And Govt Grants	100	TotalNbrOf501C3AndGovtGrants
Total Nbr Of Other Organizations	58	TotalNbrOfOtherOrganizations

Form990 Schedule I Part IV Form990ScheduleIPartIV

Field	Value	IRS element (for citing)
Identifier	SCHEDULE I, PART I, LINE 2	Identifier
Return Reference	PROCEDURES FOR MONITORING GRANT FUNDS IN THE UNITED STATES:	ReturnReference
Explanation	THE FOUNDATION AWARDS RESEARCH GRANTS BASED UPON THE GUIDANCE AND INPUT OF THE SCIENTIFIC ADVISORY BOARD AND OTHER HIGHLY REGARDED SCIENTISTS WHO SERVE ON GRANT REVIEW COMMITTEES SPECIALIZING IN PARKINSON'S RESEARCH. Goals and milestones are described within each grant award. Most Grant awards are allocated in multiple payments with key benchmarks set at the time of the grant award. MJFF's Research team closely monitors the progress of each grant awarded. There is frequent communication between grantees and MJFF staff regarding the progress of each grant. Progress is verified before additional payments are made.	Explanation

Schedule J IRS990ScheduleJ

Field	Value	IRS element (for citing)
Compensation Committee	X	CompensationCommittee
Independent Consultant	X	IndependentConsultant
Form990 Of Other Organizations	X	Form990OfOtherOrganizations
Board Or Committee Approval	X	BoardOrCommitteeApproval
Severance Payment	false	SeverancePayment
Supplemental Nonqual Retire Plan	false	SupplementalNonqualRetirePlan
Equity Based Comp Arrangement	false	EquityBasedCompArrangement
Comp Based On Revenue Of Filing Org	false	CompBasedOnRevenueOfFilingOrg
Comp Based On Revenue Related Orgs	false	CompBasedOnRevenueRelatedOrgs
Comp Based Net Earnings Filing Org	false	CompBasedNetEarningsFilingOrg
Comp Based Net Earnings Relate Orgs	false	CompBasedNetEarningsRelateOrgs
Any Non Fixed Payments	false	AnyNonFixedPayments
Initial Contract Exception	false	InitialContractException

Form990 Schedule J Part II Form990ScheduleJPartII (8 entries)

Base Compensation Filing OrgBaseCompensationFilingOrg	Comp Based On Related OrgsCompBasedOnRelatedOrgs	Bonus Filing OrgBonusFilingOrg	Bonus Related OrgsBonusRelatedOrgs	Other Compensation Filing OrgOtherCompensationFilingOrg	Other Compensation Related OrgsOtherCompensationRelatedOrgs	Deferred Comp Filing OrgDeferredCompFilingOrg	Deferred Comp Related OrgsDeferredCompRelatedOrgs	Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrg	Nontaxable Benefits Related OrgsNontaxableBenefitsRelatedOrgs	Total Compensation Filing OrgTotalCompensationFilingOrg	Total Compensation Related OrgsTotalCompensationRelatedOrgs	Comp Report Prior990 Filing OrgCompReportPrior990FilingOrg	Comp Report Prior990 Related OrgsCompReportPrior990RelatedOrgs
KATHERINE H HOOD
283344	0	180000	0	7279	0	7350	0	403	0	478376	0	0	0
JOANNE MARTZ
180396	0	45000	0	0	0	6762	0	12573	0	244731	0	0	0
Todd Sherer
225496	0	100000	0	0	0	7350	0	12573	0	345419	0	0	0
KAREN LEIES
179125	0	43000	0	0	0	6664	0	17827	0	246616	0	0	0
DEBORAH W BROOKS
275606	0	165000	0	0	0	7350	0	17827	0	465783	0	0	0
John T Grant
120796	0	15000	0	10000	0	4062	0	6127	0	155985	0	0	0
SHEILA KELLY
130287	0	16000	0	0	0	4389	0	5775	0	156451	0	0	0
Brian K Fiske
129653	0	13000	0	0	0	4053	0	12573	0	159279	0	0	0

Schedule L IRS990ScheduleL

Form990 Schedule L Part IV Form990ScheduleLPartIV

Name Of Interested Person NameOfInterestedPerson

Field	Value	IRS element (for citing)
Name Person	Donny Deutsch	NamePerson

Field	Value	IRS element (for citing)
Relationship	Board of Directors	Relationship
Amount Of Transaction	60865	AmountOfTransaction
Description Of Transaction	Design and Creative Services	DescriptionOfTransaction
Sharing Of Revenues	false	SharingOfRevenues

Form990 Schedule L Part V Form990ScheduleLPartV

Field	Value	IRS element (for citing)
Identifier	SCHEDULE L, PART IV	Identifier
Return Reference	BUSINESS TRANSACTIONS INVOLVING INTERESTED PERSONS	ReturnReference
Explanation	THE FOUNDATION INCURRED DESIGN AND CREATIVE ADVICE EXPENSES OF $60,865 FOR SERVICES RENDERED BY A COMMUNICATIONS, BRAND DEVELOPMENT AND DESIGN AGENCY, THE CHAIRMAN OF WHICH IS A FOUNDATION BOARD MEMBER. THE FOUNDATION ALSO PROVIDED A $15,000 GRANT TO A RESEARCH FIRM FOR THE PURPOSES OF PERFORMING A STUDY OF PARKINSON'S DISEASE, THE PARTNER AND MANAGING DIRECTOR OF WHICH IS A MEMBER OF THE FOUNDATION'S BOARD.	Explanation

Schedule M IRS990ScheduleM

Field	Value	IRS element (for citing)
Works Of Art		WorksOfArt
Art Historical Treasures		ArtHistoricalTreasures
Art Fractional Interest		ArtFractionalInterest
Books And Publications		BooksAndPublications
Clothing And Household Goods		ClothingAndHouseholdGoods
Cars And Other Vehicles		CarsAndOtherVehicles
Boats And Planes		BoatsAndPlanes
Intellectual Property		IntellectualProperty

Securities Publicly Traded SecuritiesPubliclyTraded

Field	Value	IRS element (for citing)
Non Cash Checkbox	X	NonCashCheckbox
Number Of Contributions	36	NumberOfContributions
Noncash Contribs Rptd F990	5398435	NoncashContribsRptdF990
Method Of Determining Revenues	FAIR VALUE	MethodOfDeterminingRevenues

Field	Value	IRS element (for citing)
Securities Closely Held Stock		SecuritiesCloselyHeldStock
Securities Prtnrshp Trust Intrsts		SecuritiesPrtnrshpTrustIntrsts
Securities Miscellaneous		SecuritiesMiscellaneous
Qualified Contrib Hist Struct		QualifiedContribHistStruct
Qualified Contrib Other		QualifiedContribOther
Real Estate Residential		RealEstateResidential
Real Estate Commercial		RealEstateCommercial
Real Estate Other		RealEstateOther
Collectibles		Collectibles
Food Inventory		FoodInventory
Drugs And Medical Supplies		DrugsAndMedicalSupplies
Taxidermy		Taxidermy
Historical Artifacts		HistoricalArtifacts
Scientific Specimens		ScientificSpecimens
Archaeological Artifacts		ArchaeologicalArtifacts
Any Property That Must Be Held	false	AnyPropertyThatMustBeHeld
Review Process Unusual NC Gifts	true	ReviewProcessUnusualNCGifts
Third Parties Used	false	ThirdPartiesUsed

Schedule O IRS990ScheduleO

General Explanation GeneralExplanation (2 entries)

IdentifierIdentifier	ExplanationExplanation	Return ReferenceReturnReference
FORM 990, PAGE 1, LINE 1 AND PAGE 2, LINE 1	FINDING THE CURE FOR PARKINSON'S TAKES AN ORGANIZATION WITH EXTRAORDINARY VISION. The Michael J. Fox Foundation for Parkinson's Research is committed to a focused, proactive strategy to do whatever it takes to speed transformative treatments to the nearly five million people living with Parkinson's disease worldwide. We are working to maximize impact by pushing basic discoveries toward clinical trials and strategically targeting resources toward critical research hurdles that other funders cannot or will not prioritize. As the largest non-government funder of Parkinson's research, we stand ready to forge a new model of what a research funding organization can be - stepping up to deliver Parkinson's solutions and, in the process, transforming a flawed biomedical research system in ways that ultimately could impact every life touched by illness or injury.
Form 990, Page 6	Line 2: TWO BOARD MEMBERS ARE MARRIED TO ONE ANOTHER. TWO BOARD MEMBERS ARE IN-LAWS. Line 11A: Process for Review of Form 990: The Finance Committee of the Board of Directors, in association with external auditors, approves the annual IRS Form 990 which is then made available to the entire Board before it is filed. Line 12A: Conflict of Interest Policy monitoring: Officers, directors and key employees complete a conflict of interest questionnaire annually. The information is reviewed by the VP, Administration, and conflicts are reviewed with the Board of Directors. Line 15: Compensation Determination: The Compensation Committee of the Board of Directors reviews and approves compensation of key employees annually. Line 19: Governing documents are available upon request. - Conflict of interest policy is available upon request. - Financial statements are available at www.michaeljfox.org.	Governance, Management and Disclosure

Schedule R IRS990ScheduleR

Form990 Schedule R Part II Form990ScheduleRPartII

Name Of Disregarded Entity NameOfDisregardedEntity

Field	Value	IRS element (for citing)
Business Name Line1	MJFF CANADA	BusinessNameLine1

Address Foreign AddressForeign

Field	Value	IRS element (for citing)
Address Line1	365 Bay Street Suite 899	AddressLine1
City	Toronto	City
Province Or State	Ontario	ProvinceOrState
Country	CA	Country

Field	Value	IRS element (for citing)
Primary Activities	RESEARCH	PrimaryActivities
Legal Domicile Foreign Country	CA	LegalDomicileForeignCountry

Direct Controlling Entity Name DirectControllingEntityName

Field	Value	IRS element (for citing)
Business Name Line1	MJFF (US)	BusinessNameLine1

Field	Value	IRS element (for citing)
Receipt Of Int Ann Rents Royalties	false	ReceiptOfIntAnnRentsRoyalties
Gift Grant Or Cap Contr To Other Org	false	GiftGrantOrCapContrToOtherOrg
Gift Grant Or Cap Contr Fr Other Org	true	GiftGrantOrCapContrFrOtherOrg
Loans Or Guarantees To Other Org	false	LoansOrGuaranteesToOtherOrg
Loans Or Guarantees From Other Org	false	LoansOrGuaranteesFromOtherOrg
Sale Of Assets To Other Org	false	SaleOfAssetsToOtherOrg
Purchase Of Assets From Other Org	false	PurchaseOfAssetsFromOtherOrg
Exchange Of Assets	false	ExchangeOfAssets
Rental Of Facilities To Other Orgs	false	RentalOfFacilitiesToOtherOrgs
Rental Of Facilities Fr Other Orgs	false	RentalOfFacilitiesFrOtherOrgs
Perform Of Services For Other Orgs	false	PerformOfServicesForOtherOrgs
Perform Of Services By Other Orgs	false	PerformOfServicesByOtherOrgs
Sharing Of Facilities	false	SharingOfFacilities
Sharing Of Paid Employees	false	SharingOfPaidEmployees
Reimbursement Paid To Other Org	false	ReimbursementPaidToOtherOrg
Reimbursement Paid By Other Org	false	ReimbursementPaidByOtherOrg
Other Transfer To Other Org	false	OtherTransferToOtherOrg
Other Transfer From Other Org	false	OtherTransferFromOtherOrg

Transactions Related Orgs Table TransactionsRelatedOrgsTable

Name Of Other Organization NameOfOtherOrganization

Field	Value	IRS element (for citing)
Business Name Line1	THE MICHAEL J FOX FOUNDATION (CANADA)	BusinessNameLine1

Field	Value	IRS element (for citing)
Transaction Type	C	TransactionType
Amount Involved	194518	AmountInvolved